Two Medtronic Studies Highlight Drug Coated Balloon’s Ability to Treat Long Lesions
Medtronic Wednesday released new data from two separate studies of its In.Pact Admiral drug-coated balloon, which shows the balloon successfully treated long lesions in the superficial femoral and popliteal arteries.
The devicemaker said treatment with the In.Pact delivered a 6 percent rate of target lesion revascularization and primary patency of 91.1 percent at 360 days after the procedure in the global study, and at 360 days the Italian study delivered 4 percent and 89.3 percent, respectively.
Additionally, 94 percent of patients had no major adverse events and no major target limb amputations after 12 months, Medtronic said.
The In.Pact DCB received FDA approval last December for treating lesions up to 18 cm in length. It was CE marked in 2009 for a broader indication that doesn’t specify lesion length. — Kellen Owings